HIV Treatment

HIV treatmentThe IMPAACT HIV Treatment Scientific Committee aims to evaluate the pharmacokinetics (PK), safety, and drug interactions of new and existing antiretroviral (ARV) agents and formulations leading to optimal dosing and licensing for infants, children, adolescents, and pregnant/postpartum people living with HIV. Despite licensure of more than 30 ARVs in adults, most of the new ARVs have not been evaluated for PK, safety and dosing in pregnant people, children, and especially newborns and infants. Priorities include evaluation of PK properties of ARVs and related drugs during pregnancy and postpartum as well as PK and safety of ARV and related drugs for infants, children, and adolescents.

Committee Contacts

Chair: Ted Ruel
Vice Chair: Moherndran Archary
Operations Center: Katie McCarthy and Michael Whitton



Studies Within This Research Area